P
Pedram Rafiei
Researcher at University of Saskatchewan
Publications - 13
Citations - 2456
Pedram Rafiei is an academic researcher from University of Saskatchewan. The author has contributed to research in topics: Drug delivery & PLGA. The author has an hindex of 10, co-authored 13 publications receiving 2087 citations. Previous affiliations of Pedram Rafiei include Shiraz University of Medical Sciences & University of Toronto.
Papers
More filters
Journal ArticleDOI
Hydrogel Nanoparticles in Drug Delivery
TL;DR: Hydrogel nanoparticles have gained considerable attention in recent years as one of the most promising nanoparticulate drug delivery systems owing to their unique potentials via combining the characteristics of a hydrogel system with a nanoparticle, each with its own advantages and drawbacks.
Journal ArticleDOI
Pharmacokinetic consequences of pegylation.
TL;DR: The main pharmacokinetic outcomes of pegylation are summarized as changes occurring in overall circulation life-span, tissue distribution pattern, and elimination pathway of the parent drug/particle.
Journal ArticleDOI
Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Pedram Rafiei,Azita Haddadi +1 more
TL;DR: Surface modification of PLGA NPs contributed to more pronounced docetaxel blood concentration, which confirms the role of PEG in conferring long-circulation properties to NPs, and the mode of changes made to pharmacokinetics and biodistribution is attributed to the size and surface properties of NPs.
Journal ArticleDOI
A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach.
TL;DR: The purpose of the current review is to present an insightful summary of pharmacokinetic analyses of nanotechnology-based drug delivery systems along with a critical review of recent findings.
Journal ArticleDOI
Encapsulation of valproate-loaded hydrogel nanoparticles in intact human erythrocytes: a novel nano-cell composite for drug delivery.
TL;DR: In this article, a novel drug delivery system possessing prolonged release behavior is introduced to the field of carrier erythrocytes and nanotechnology-based drug delivery, where encapsulation of valproate-loaded nanogels inside human erythropoietin (EPO) cells as a novel nanocell composite was the objective of the study.